Mylan Strikes Licensing Deal for Therapy Aimed at Treating Covid-19 Patients
May 12 2020 - 5:12PM
Dow Jones News
By Micah Maidenberg
Mylan NV said Tuesday it struck a deal to license remdesivir, a
therapy that may treat patients with Covid-19, from Gilead Sciences
Inc.
Under terms of the agreement, Mylan has the right to manufacture
and distribute remdesivir in 127 low- and middle-income countries
including India, Mylan said in a statement.
The licensing deal is non-exclusive, the statement says.
Two global clinical trials focused on remdesivir have shown
positive results, reducing the recovery time for patients with
Covid-19, Mylan said in a statement.
"The full efficacy and safety of the treatment are still under
investigation," the company said.
The treatment was granted an emergency use authorization to
treat hospitalized Covid-19 patients in the U.S., Mylan said. It is
recommended for compassionate use in Europe and recently received
regulatory approval in Japan, according to the company.
Remdesivir is the 10th medicine licensed to Mylan by Gilead.
Write to Micah Maidenberg at micah.maidenberg@wsj.com
(END) Dow Jones Newswires
May 12, 2020 16:57 ET (20:57 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2023 to Apr 2024